Stenbolone acetate
Appearance
(Redirected from Anatrofin)
Clinical data | |
---|---|
Trade names | Stenobolone, Anatrofin |
Other names | RS-2106; S-3760; 2-Methyl-4,5α-dihydro-δ1-testosterone 17β-acetate; 2-Methyl-δ1-DHT 17β-acetate; 2-Methyl-5α-androst-1-en-17β-ol-3-one 17β-acetate |
Routes of administration | Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H32O3 |
Molar mass | 344.495 g·mol−1 |
3D model (JSmol) | |
| |
|
Stenbolone acetate (USAN ) (brand name Stenobolone, Anatrofin; former developmental code names RS-2106, S-3760), also known as 2-methyl-4,5α-dihydro-δ1-testosterone 17β-acetate (2-methyl-δ1-DHT 17β-acetate) or as 2-methyl-5α-androst-1-en-17β-ol-3-one 17β-acetate, is a synthetic, injected anabolic–androgenic steroid (AAS) and derivative of dihydrotestosterone (DHT) which has been marketed in Spain.[1][2][3]
It is the C17β acetate ester of stenbolone, which is structurally related to 1-testosterone (Δ1-DHT; dihydroboldenone) and to drostanolone (2α-methyl-DHT).[1][2][3]
See also
[edit]References
[edit]- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1116. ISBN 978-1-4757-2085-3.
- ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 962–. ISBN 978-3-88763-075-1.
- ^ a b Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.